Here’s a write-up by an MD who disagrees with you and thinks patients receiving Opdivo in second-line NSCLC should be (and generally will be) tested for PD-L1 status:
I don’t think this author has convincingly made a case for Opdivo inferiority relative to Taxotere in PD-L1-negative patients, but there may be enough murkiness that many docs prescribing Opdivo in second-line NSCLC will opt to test for PD-L1 after all.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.